Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 801–900 of 3,116
From pathophysiology to novel approaches for obesity-associated hypertension
Kanbay, M., Yayci, E., Genc, C., Çöpür, S., Aktaş, Ö. Y., Sarafidis, P. A., Covic, A. C., Ortíz, A., & Laffin, L. J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf218 · Cited by 12
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Walsh, M. N., Køber, L., Sliwa, K. S., Adamo, M., Agarwal, A., Banerjee, A., Bozkurt, B., Čikeš, M., Damasceno, A., Desai, A. S., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag500 · Cited by 33
Nguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M., Paterson, A. D., & Dash, S. (2024) · Clinical Obesity · doi:10.1111/cob.12676 · Cited by 11
Mapelli, M., Rubbo, F. M., Costantino, S., Amelotti, N., & Agostoni, P. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.37 · Cited by 14
Current and Future of Heart Failure Care in Asia
Yoo, S. G. K., Ahmed, M., & Sweitzer, N. K. (2024) · International Journal of Heart Failure · doi:10.36628/ijhf.2024.0033 · Cited by 14
Younossi, Z. M., Kalligeros, M., Wong, V. W., Al-Naamani, K. M., Tacke, F., Tsochatzis, E. A., Crespo, J., El‐Kassas, M., Bril, F., Arrese, M. A., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.030 · Cited by 28
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037510 · Cited by 12
Why do obesity drugs seem to treat so many other ailments?
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-03074-1 · Cited by 17
Larsen, A. T., Mohamed, K. E., Melander, S. A., Karsdal, M. A., & Henriksen, K. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00092.2024 · Cited by 12
Ala, M., & Aleaba, M. M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02459-3 · Cited by 12
Filtz, A., Shapiro, M. D., Whelton, P. K., Návar, A. M., Rodríguez, F., Martin, S. S., Gulati, M., Blankstein, R., Ridker, P. M., Bhatt, D. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101357 · Cited by 10
“Among modifiable risk factors, hypertension is the most prominent — though yet to be proven — to expect a lower incidence of HF [105].”
Basdas, R., Martínez-Cereijo, J. M., Fernández, Á. L., Reija, L., Cabaleiro, A., Bravo, S. B., González‐Juanatey, J. R., & Eirás, S. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.03.009 · Cited by 16
Understanding the roles of salt-inducible kinases in cardiometabolic disease
Shi, F. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1426244 · Cited by 12
Kelkar, R., Barve, N., Kelkar, R., Kharel, S., Khanapurkar, S., & Yadav, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1453297 · Cited by 10
Carris, N. W., Wallace, S., DuCoin, C. G., Mhaskar, R. S., Stern, M., & Bunnell, B. E. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0464 · Cited by 13
Fuller, T., Newberry, Z., Nasir, M., & Tondt, J. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2024.04.007 · Cited by 9
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
Preventing the progression of cirrhosis to decompensation and death
Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 40
Malnutrition with use of GLP-1 agonists is an underestimated real world harm
Fallows, E. (2025) · BMJ · doi:10.1136/bmj.r1512 · Cited by 12
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
Self-citationNazarenko, N., Chen, Y., Borkowski, P., Biavati, L., Parker, M., Vargas‐Pena, C., Chowdhury, I. Z., Bock, J. M., Garg, V., Bhakta, S., et al. (2025) · HIV Medicine · doi:10.1111/hiv.13760 · Cited by 11
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.019 · Cited by 12
Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health
Grant, C. H., & Bell, S. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.33 · Cited by 12
de Figueiredo, I. R., Simas, F. S., Ghiletchi, A., Torres, J. O., & Silva‐Nunes, J. (2026) · Obesity · doi:10.1002/oby.70098 · Cited by 14
“A 20% reduction in the primary endpoint (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in the semaglutide group was shown [9, 10].”
A Revolution in the Treatment of Obesity
Spector, R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.05.023 · Cited by 10
Ganeshalingam, A. A., Uhrenholt, N. G., Arnfred, S., Gæde, P., Bilenberg, N., & Frystyk, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077173 · Cited by 12
Lu, Y., Liu, Y., Jastreboff, A. M., Khera, R., Ndumele, C. D., Rodríguez, F., Watson, K. E., & Krumholz, H. M. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.123.010640 · Cited by 9
Ruggiero, R., Longo, M., Mascolo, A., Nuzzo, M. D., Laino, L. V., Caruso, P., D'Amato, R., Rafaniello, C., Maiorino, M. I., Esposito, K., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178004 · Cited by 12
Hviid, K. V. R., Banasik, K., Mortensen, L. H., Madsbad, S., Strandberg‐Larsen, K., Geiker, N. R. W., Westergaard, D., & Nielsen, H. S. (2026) · Human Reproduction Open · doi:10.1093/hropen/hoag015 · Cited by 21
“…clinical trials and patient-reported outcomes, highlighting its efficacy and safety profile (Kushner et al. , 2020; Davies et al. , 2021; Rubino et al. , 2021; Wadden et al. , 2021; Wilding et al. , 2021; Garvey et al. , 2022; Weghuber et al. , 2022; Lincoff et al. , 2023; Wilkinson et al. , 2023).”
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Chronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 12
Amigó, N., Torné, P., Nordestgaard, L. T., Barbagallo, F. D. G., Merino, C., Magni, P., González-Lleó, A. M., Andreychuk, N., Catapano, A. L., Masana, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178284 · Cited by 10
Brown, A., Mellor, D., Makaronidis, J., Shuttlewood, E., Miras, A. D., & Pournaras, D. J. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12700 · Cited by 9
Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives
Horváth, D., Stráner, P., Taricska, N., Fazekas, Z., Menyhárd, D. K., & Perczel, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01553 · Cited by 13
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241309896 · Cited by 9
Geschlechterspezifische Aspekte kardiovaskulärer Erkrankungen
Baessler, A., Bauer, P., Becker, M., Berrisch-Rahmel, S., Goldmann, B. U., Grünig, E., Hamm, C., Meder, B., Kindermann, I., Ong, P., et al. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00694-9 · Cited by 11
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 12
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis
Rebelo, T. G., de Araujo Paysano, M. L. B., Matheus, G. T. F. U., Ribeiro, D. M., Said, T. B., & Kelly, F. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133683 · Cited by 9
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
“GLP-1 medicines reduce rates of cardiovascular disease 93,94 and decrease rates of heart disease and all-cause mortality in individuals with cancer with T2D using immune checkpoint inhibitors 95 .”
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf065 · Cited by 8
Menopause, epicardial adiposity and preserved ejection fraction heart failure
Museedi, A. S., Samson, R., & Jemtel, T. H. L. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132478 · Cited by 11
Singh, A., & Nissen, S. E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0122 · Cited by 11
Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options
Schmitz, S. H., Saunders, K. H., & Aronne, L. J. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.09.003 · Cited by 12
Halle, M., & Papadakis, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae091 · Cited by 8
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Ostrominski, J. W., Wagholikar, K. B., Olsson, K., Ünlü, O., Zelle, D., Kumar, S., Smith, A. M., Toliver, J. C., Michalak, W., Fabricatore, A. N., et al. (2024) · Obesity · doi:10.1002/oby.24186 · Cited by 8
Self-citationEffects of liraglutide among patients with psoriatic arthritis and obesity
Nicolau, J., Nadal, A., Ros, I., et al. (2025) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2025.501809 · Cited by 8
Tong, X., Song, X., Zhang, Y., & Zhao, Q. (2024) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2024.2380422 · Cited by 13
Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Capoccia, D., Leonetti, F., Natali, A., Tricò, D., Perrini, S., Sbraccia, P., Guglielmi, V., & On behalf of the Italian Society of Diabetes (SID) (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02317-x · Cited by 11
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat, J., Shah, N. P., Agarwala, A., Khan, M. S., & Butler, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01214-6 · Cited by 11
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Vilsbøll, T., Stellfeld, M., Aroda, V. R., Dandanell, S., David, J., Kristiansen, C. T. P., Rasmussen, S., Roberts, F. L., & Hegedűs, L. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70291 · Cited by 12
Madhu, S. V., Kapoor, N., Das, S., Raizada, N., & Kalra, S. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_680_25 · Cited by 18
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“All-cause hospitalization was reported as an outcome in four trials [42, 48, 51, 80].”
InfluentialManaging Obesity in Heart Failure: Latest Evidence and Knowledge Gaps
Ibrahim, R., Pham, H. N., Vest, A. R., & William, P. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01056-0 · Cited by 11
Grabowski, H. G., & Long, G. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2323903 · Cited by 8
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation
Sgarra, L., Desantis, V., Matteucci, A., Caccavo, V. P., Troisi, F., Monaco, A. D., Mangini, F., Katsouras, G., Guaricci, A. I., Dadamo, M. L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030660 · Cited by 10
Onzi, T. R., Salgado, W., Bastos, E. L. D. S., Dantas, A. C. B., Silva, L. B., Albano, A., Tristão, L. S., dos Santos, C. L., Bernardo, W. M., & Pedrotti, M. (2024) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-6720202400021e1814 · Cited by 10
Pharmacotherapy for older people with obesity
Boyle, L. D., Akbaş, F., Yazıcı, D., McGowan, B. M., & Yumuk, V. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.05.006 · Cited by 10
Duhan, S., Kurpad, K. P., Keisham, B., Shtembari, J., Brener, A., Kanakadandi, U. B., Garg, A., Adoni, N. A., & Mehta, S. S. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133604 · Cited by 8
Riehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction
Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N. A., Barot, S. V., & Shah, G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040919 · Cited by 14
“10 Notably, our study in patients with CTRCD found a larger relative risk reduction in all-cause mortality and HF hospitalizations than those trials, which is likely reflective of differences in end points, patient characteristics, and potential unmeasured confounders given the retrospective nature…”
Dardari, Z., Yao, Z., Zhang, J., Bakoyannis, G., Nan, H., Staten, L. K., Jha, K. K., Tasdighi, E., Jelwan, Y. A., Burka, S., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.075327 · Cited by 15
Seddio, A. E., Vasudevan, R. S., Gouzoulis, M. J., Ansah-Twum, J. K., Grauer, J. N., & Rubin, L. E. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.003 · Cited by 14
Rao, Z., Tang, Y., Zhu, J., Lu, Z., Chen, Z., Wang, J., Bao, Y., Mukondiwa, A. V., Wang, C., Wang, X., et al. (2025) · Nanomaterials · doi:10.3390/nano15050346 · Cited by 8
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
Gasoyan, H., Schulte, R. J., Boyer, C., Casacchia, N. J., Butsch, W. S., Le, P. N. B., Aminian, A., Griebeler, M. L., Burguera, B. G., & Rothberg, M. B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70660 · Cited by 13
“Treatment with semaglutide also prevents cardiovascular events, particularly in patients with established atherosclerotic cardiovascular disease [9] and slows progression of kidney disease in those with T2D and chronic kidney disease [10].”
Šedová, P., Vrablík, M., Kala, P., Ošťádal, P., Tichopád, A., Tomek, A., Mikulík, R., Donin, G., Littnerová, S., Kent, J. A., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag002 · Cited by 9
Ciconte, G., Salerno, R., Fuga, A., Vuturo, A., Boccellino, A., Negro, G., Rondine, R., Ballarotto, M., Ciaccio, C., Izzo, A., et al. (2026) · EP Europace · doi:10.1093/europace/euag018 · Cited by 18
“11,12 Beyond their systemic metabolic effects, GLP-1RA therapy has been associated with reductions in epicardial fat thickness, inflammatory activation, and oxidative stress, mechanisms that are mechanistically linked to atrial remodelling and AF progression.”
Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
Lee, D., & Capeau, J. (2024) · AIDS · doi:10.1097/qad.0000000000003816 · Cited by 8
Lin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 8
Pop, A. S. K., Dănilă, M. D., Giuchici, S., Buriman, D. G., Lolescu, B. M., Sturza, A., Muntean, D. M., & Lascu, A. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0384 · Cited by 11
Shah, N. P., Lü, R., Haddad, F., Shore, S., Schaack, T., Mega, J. L., Pagidipati, N. J., Palaniappan, L. P., Mahaffey, K. W., Shah, S. H., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100646 · Cited by 10
Cimellaro, A., Cavallo, M., Mungo, M., Suraci, E., Spagnolo, F., Addesi, D., Pintaudi, M., & Pintaudi, C. (2024) · Medicina · doi:10.3390/medicina60091542 · Cited by 12
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 11
Should the Incretin hype be the same for older adults: Promise + cautions
Batsis, J. A., Porter Starr, K. N., & Villareal, D. T. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18816 · Cited by 8
Stanley, C., Mallik, R., Hamid, N., Jassil, F. C., Reuven, V., Ruwona, T., Dicken, S. J., Qamar, S., Norton, B. C., Kingett, H., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04416-4 · Cited by 18
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
Practical strategies to manage obesity in type 2 diabetes
Rodbard, H. W., Barnard-Kelly, K. D., Pfeiffer, A. F. H., Mauersberger, C., Schnell, O., & Giorgino, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15556 · Cited by 10
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Vallianou, K., Diakoumopoulou, E., Makrilakis, K., & Tentolouris, N. (2025) · Biomolecules · doi:10.3390/biom15091284 · Cited by 15
Henney, A. E., Riley, D. R. J., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025) · Liver International · doi:10.1111/liv.70367 · Cited by 11
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Haggerty, T. S., Dekeseredy, P., Bailey, J., Cowher, A. E., Baus, A., & Davisson, L. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100120 · Cited by 13
Cost-Related Prescription Drug Rationing by Adults With Obesity
Chen, A. S., Borden, C. G., Canavan, M. E., Ross, J. S., Oladele, C. R., & Lipska, K. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33000 · Cited by 8
Fu, W., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., Liu, L., & Li, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16581 · Cited by 8
Çelik, Ö., Yazıcı, D., Ciudin, A., Macut, D., Micić, D., Yumuk, V., & Yıldız, B. O. (2025) · Obesity Facts · doi:10.1159/000547055 · Cited by 14
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Basile, C., Merolla, A., Mancusi, C., Luca, C. D., Fucile, I., Canonico, M. E., Giugliano, G., Orso, F., Morisco, C., & Esposito, G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf560 · Cited by 17
Watts, G. F., Zadeh, S. S. T., & Chan, D. C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae321 · Cited by 9
HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals
Capeau, J., Lagathu, C., Ayissi, K. N., Fève, B., & Béréziat, V. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.05.005 · Cited by 8
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes
Patti, A. M., Giglio, R. V., Ciaccio, M., Stoian, A. P., Salmen, T., Bica, I.-C., Rangraze, I. R., El‐Tanani, M., Rizzo, M., & Rizvi, A. A. (2025) · Medicina · doi:10.3390/medicina61040664 · Cited by 9
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
Wang, J., Wang, N., Guo, H., Niu, X., Hu, S., Pan, X., Wang, M., Zhang, D., Song, L., & Sun, B. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf178 · Cited by 8
Petermann-Rocha, F. E., Apolinar‐Jiménez, E., Nazar, G., Diaz‐Toro, F., Celis, A., Deo, S. V., Ferrari, G., & O’Donovan, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15528 · Cited by 11
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
